Q-omics provides the consensus-scored WDR86 profile across patient tissues and cancer cell-line models. WDR86 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, WDR86 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, WDR86 RNA expression shows 16,481 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KICH, and TGCT as cancer lineages where WDR86 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR86 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR86 survival associations across molecular data types. WDR86 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR86 RNA expression–survival associations across cancer types. High WDR86 expression shows unfavorable associations in KIRC, KIRP and COAD, but favorable associations in SKCM, LGG and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for WDR86 RNA expression.
This table summarizes WDR86 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for WDR86. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR86 shows lower tumor expression in KICH, BRCA, KIRP and KIRC and higher tumor expression in HNSC and LUAD. The KICH box plot shows higher WDR86 RNA expression in normal versus tumor tissue (log2 FC = −1.425, t-test p < 0.001).
This table shows molecular features associated with WDR86 in patient tissues and cancer cell lines. In patient samples, WDR86 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR86 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
